StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) stock

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$292.82−1.73 (-0.59%)

Close on Nov 17, 2026Market cap $517.45BP/E 82.7Yield 2.27%

AbbVie operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

AbbVie's operating cash flow for the twelve months ending Jun 30, 2026 was $19.51B, up 1.2% year over year. For fiscal 2025 it was $19.03B, up 1.2% from the year before. Over ten years it grew 9.7% a year on average. The highest annual figure on record is $24.94B in fiscal 2022.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$19.03B+1.2%
FY2024Dec 31, 2024$18.81B-17.7%
FY2023Dec 31, 2023$22.84B-8.4%
FY2022Dec 31, 2022$24.94B+9.5%
FY2021Dec 31, 2021$22.78B+29.5%
FY2020Dec 31, 2020$17.59B+32.0%
FY2019Dec 31, 2019$13.32B-0.8%
FY2018Dec 31, 2018$13.43B+34.8%
FY2017Dec 31, 2017$9.96B+41.5%
FY2016Dec 31, 2016$7.04B-6.6%
FY2015Dec 31, 2015$7.54B+112.3%
FY2014Dec 31, 2014$3.55B-43.4%
FY2013Dec 31, 2013$6.27B-1.2%
FY2012Dec 31, 2012$6.35B+1.6%
FY2011Dec 31, 2011$6.25B–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.44B-33.3%
Q1 FY2026Mar 31, 2026$3.83B+134.2%
Q4 FY2025Dec 31, 2025$5.22B-26.0%
Q3 FY2025Sep 30, 2025$7.02B+29.0%
Q2 FY2025Jun 30, 2025$5.15B+126.9%
Q1 FY2025Mar 31, 2025$1.64B-59.5%
Q4 FY2024Dec 31, 2024$7.05B+48.3%
Q3 FY2024Sep 30, 2024$5.45B-28.1%
Q2 FY2024Jun 30, 2024$2.27B-64.1%
Q1 FY2024Mar 31, 2024$4.04B-3.6%
Q4 FY2023Dec 31, 2023$4.75B-36.0%
Q3 FY2023Sep 30, 2023$7.57B-0.4%
Q2 FY2023Jun 30, 2023$6.32B+26.3%
Q1 FY2023Mar 31, 2023$4.19B-14.6%
Q4 FY2022Dec 31, 2022$7.43B+46.4%
Q3 FY2022Sep 30, 2022$7.60B-4.2%
Q2 FY2022Jun 30, 2022$5.01B+2.4%
Q1 FY2022Mar 31, 2022$4.91B+0.6%
Q4 FY2021Dec 31, 2021$5.08B+4.6%
Q3 FY2021Sep 30, 2021$7.94B+36.1%
Q2 FY2021Jun 30, 2021$4.89B+58.3%
Q1 FY2021Mar 31, 2021$4.88B+27.8%
Q4 FY2020Dec 31, 2020$4.85B+48.2%
Q3 FY2020Sep 30, 2020$5.83B+28.0%
Q2 FY2020Jun 30, 2020$3.09B+24.7%
Q1 FY2020Mar 31, 2020$3.82B+26.5%
Q4 FY2019Dec 31, 2019$3.28B-3.4%
Q3 FY2019Sep 30, 2019$4.56B+0.7%
Q2 FY2019Jun 30, 2019$2.48B-13.6%
Q1 FY2019Mar 31, 2019$3.02B+14.1%
Q4 FY2018Dec 31, 2018$3.39B+31.3%
Q3 FY2018Sep 30, 2018$4.52B+38.3%
Q2 FY2018Jun 30, 2018$2.87B+43.1%
Q1 FY2018Mar 31, 2018$2.65B+25.8%
Q4 FY2017Dec 31, 2017$2.58B+67.7%
Q3 FY2017Sep 30, 2017$3.27B+125.0%
Q2 FY2017Jun 30, 2017$2.00B–
Q1 FY2017Mar 31, 2017$2.10B–
Q4 FY2016Dec 31, 2016$1.54B–
Q3 FY2016Sep 30, 2016$1.45B–

More AbbVie figures

See a number that looks wrong?